14.62 (-%)
As of Nov 20, 2024
Source:
Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in four Phase 3 registrational studies targeting lung and gastrointestinal cancers.
Country | United States |
Headquarters | hayward, california |
Phone Number | (510) 694-6200 |
Industry | manufacturing |
CEO | Terry Rosen |
Website | www.arcusbio.com |